News

July 12, 2017

Eli Lilly and Company to Present More Than 40 Abstracts at the Alzheimer's Association International Conference® 2017 (AAIC® 2017)
Data highlights include important health outcomes data emphasizing the need for timely detection and management of Alzheimer's disease INDIANAPOLIS, July 12, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it will present findings from more than 40 research studies at the upcoming Alzheimer's Association Intern...

July 10, 2017

Renowned Television Personality Don Francisco Introduces New Initiative to Help Dispel Myths About Diabetes and Insulin Treatment
INDIANAPOLIS and RIDGEFIELD, Conn., July 10, 2017 /PRNewswire/ -- Popular television host and legendary entertainer, Don Francisco, is joining Lilly and Boehringer Ingelheim to launch a new awareness initiative, Basado en Hechos, to help address common misconceptions about type 2 diabetes and insulin treatment. As part of this partnership, ...

July 10, 2017

FDA Grants Priority Review for Lilly's Abemaciclib for the Treatment of Advanced Breast Cancer
INDIANAPOLIS, July 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its New Drug Application (NDA) for abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, and given the NDA a Priority Review designation. The NDA includes the company's submissi...

July 3, 2017

Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis
INDIANAPOLIS, July 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that Japan's Ministry of Health, Labor and Welfare (MHLW) granted marketing approval for Olumiant® (baricitinib) 2-mg and 4-mg tablets for the treatment of rheumatoid arthritis (RA) (including the prevention of str...

June 27, 2017

Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour
INDIANAPOLIS, June 27, 2017 /PRNewswire/ -- For the 22,000 children who attend diabetes camp each year, feelings of isolation that may accompany type 1 diabetes can be overcome by fun experiences and new friends who say, "you are not alone." Lilly Diabetes understands the importance of the diabetes camp experience for those taking the first steps t...

June 16, 2017

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that the majority of patients with active psoriatic arthritis (PsA) treated with Taltz® (ixekizumab) exhibited either no progression or minimal progression of radiographic structural joint damage through 52 weeks of treatment. Detailed results from the exten...

June 16, 2017

New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017
INDIANAPOLIS, June 16, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced a new pooled analysis of data from eight Olumiant® (baricitinib) clinical trials, showing that baricitinib-treated and placebo-treated patients with moderate-to-severe rheumatoid arthritis (RA) had similar rates of serio...

June 15, 2017

EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate Response or Intolerance to TNF Inhibitors
Taltz also demonstrated significant improvements in key secondary measures at 24 weeks INDIANAPOLIS, June 15, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients with active psoriatic arthritis (PsA) who had inadequate response to one or two TNF inhibitors or were intolerant of TNF inhibitors treated with T...

June 13, 2017

Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017)
INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that new data on safety and long-term efficacy from the Olumiant® (baricitinib) clinical trials will be presented in 21 abstracts, including one oral presentation, at the Annual European Congress of Rheumatology (...

June 13, 2017

U.S. FDA Approves Humalog® Junior KwikPen® for the Treatment of Diabetes
INDIANAPOLIS, June 13, 2017 – The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Humalog® Junior KwikPen® for the treatment of diabetes. Humalog Junior KwikPen is a prefilled pen with half-unit dosing capability, enabling finer dose adjustment for those who need it.

June 13, 2017

Jardiance® (empagliflozin) analysis reinforces established safety profile
RIDGEFIELD, Conn., and INDIANAPOLIS, June 13, 2017 /PRNewswire/ -- An analysis of pooled safety data from 19 studies, including the EMPA-REG OUTCOME® trial, involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower l...

June 13, 2017

Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab
Global Phase 3 program is studying potential new treatment option for millions of people living with chronic pain associated with osteoarthritis and chronic low back pain Acts in a different manner than opioids and other analgesics NEW YORK & INDIANAPOLIS-...

June 12, 2017

Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease
RIDGEFIELD, Conn. and INDIANAPOLIS, June 12, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to conduct a new, large clinical outcomes trial investigating Jardiance® (empagliflozin) tablets for the treatment of people with chronic kidney disease. The trial will enroll people with chronic ki...

June 10, 2017

Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS
INDIANAPOLIS, June 10, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today positive results from three Phase 3 studies of galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, including late-breaking data on several key secondary endpoints for galcanezumab compared to placebo at both stud...

June 8, 2017

Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting
INDIANAPOLIS, June 8, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from 14 abstracts, including late-breaking Phase 3 data for two investigational treatments for migraine, at the American Headache Society (AHS) annual scientific meeting, taking place June 8-11 in Boston. Lilly will highlight new, Phase 3 primary ...

June 3, 2017

Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer
INDIANAPOLIS, June 3, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results from the Phase 3 MONARCH 2 study showed that abemaciclib, a cyclin-dependent kinase (CDK)4 & 6 inhibitor, in combination with fulvestrant, significantly improved progression-free survival (PFS) compared to treatment with fulvestrant alone in wo...

June 1, 2017

Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®
RIDGEFIELD, Conn. and INDIANAPOLIS, June 1, 2017 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present 33 abstracts highlighting the companies' wide range of diabetes treatment options at the 77th American Diabetes Association's (ADA) Scientific Sessions® in San Diego, June 9-13. With compounds represen...

May 31, 2017

Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
INDIANAPOLIS, May 31, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RANGE study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement. The Phase 3 global, randomized, double-blinded, placebo-controlled trial is evalu...

May 17, 2017

Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017
INDIANAPOLIS, May 17, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new research demonstrating advances in the Company's oncology pipeline and product portfolio will be presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 2-6, 2017. Data underscore a strategic focus ...

May 12, 2017

Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine
INDIANAPOLIS, May 12, 2017 /CNW/ -- Eli Lilly and Company (NYSE: LLY) announced today that galcanezumab, an investigational treatment for the prevention of episodic and chronic migraine, met its primary endpoint in three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) demonstrating statistically significant reductions in the number of monthly migra...

Showing 1-20 of 33 Page: 1 2  Next 20